Expression of adipocyte-derived leucine aminopeptidase in endometrial cancer: Association with tumor grade and CA-125

Tumor Biology

Volumn 24, Issue 4, 2003, Pages 203-208

  Kazeto, Hideo ^a   Nomura, Seiji ^a   Ito, Norio ^a   Ito, Tomomi ^a   Watanabe, Yoshiteru ^a   Kajiyama, Hiroaki ^a   Shibata, Kiyosumi ^a   Ino, Kazuhiko ^a   Tamakoshi, Koji ^a   Hattori, Akira ^b   Kikkawa, Fumitaka ^a   Nagasaka, Tetsuro ^c   Tsujimoto, Masafumi ^b   Mizutani, Shigehiko ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b RIKEN   (Japan)

^c NAGOYA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Aminopeptidase; Endometrial cancer; Immunohistochemistry

Indexed keywords

ADIPOCYTE DERIVED LEUCINE AMINOPEPTIDASE; ANGIOTENSIN; CA 125 ANTIGEN; CD34 ANTIGEN; CYTOSOL AMINOPEPTIDASE; UNCLASSIFIED DRUG;

ADULT; ANGIOGENESIS; ARTICLE; CANCER GRADING; CANCER GROWTH; CELL DIFFERENTIATION; CONTROLLED STUDY; CORRELATION ANALYSIS; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; ENZYME METABOLISM; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION;

EID: 0345059335     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000074431     Document Type: Article

References (41)

1. Taylor A: Aminopeptidases: Structure and function. FASEB J 1993;7:290-298.
2. Turner AJ, dos Santos Medeiros M, Hooper NM: The molecular biology of GPI-anchored border hydrolases. Cell Biol Int Rep 1991;15:1083-1993.
3. Santos AN, Langner J, Herrmann M, Riemann D: Aminopeptidase N/CD13 is directly linked to signal transduction pathways in monocytes. Cell Immunol 2000;201:22-32.
4. Bhagwat SV, Petrovic N, Okamoto Y, Shapiro LH: The angiogenic regulator CD13/APN is a transcriptional target of Ras signaling pathways in endothelial morphogenesis. Blood 2003;101:1818-1826.
5. Imai K, Kanzaki H, Mori T: Cell surface peptidases in human endometrium. Mol Hum Reprod 1996;2:425-431.
6. Kajiyama H, Kikkawa F, Suzuki T, Shibata K, Ino K, Mizutani S: Prolonged survival and decreased invasive activity attributable to dipeptidyl peptidase IV overexpression in ovarian carcinoma. Cancer Res 2002;62:2753-2757.
7. Kajiyama H, Kikkawa F, Maeda O, Suzuki T, Ino K, Mizutani S: Increased expression of dipeptidyl peptidase IV in human mesothelial cells by malignant ascites from ovarian carcinoma patients. Oncology 2002;63:158-165.
8. Hattori A, Matsumoto H, Mizutani S, Tsujimoto M: Molecular cloning of adipocyte-derived leucine aminopeptidase highly related to placental leucine aminopeptidase/oxytocinase. J Biochem (Tokyo) 1999;125:931-938.
9. Keller SR, Scott HM, Mastick CC, Aebersold R, Lienhard GE: Cloning and characterization of a novel insulin-regulated membrane aminopeptidase from Glut4 vesicles. J Biol Chem 1995;270:23612-23618.
10. Rogi T, Tsujimoto M, Nakazato H, Mizutani S, Tomoda Y: Human placental leucine aminopeptidase/oxytocinase: A new member of type II membrane-spanning zinc metallopeptidase family. J Biol Chem 1996;271:56-61.
11. Hattori A, Kitatani K, Matsumoto H, Miyazawa S, Rogi T, Tsuruoka N, Mizutani S, Natori Y, Tsujimoto M: Characterization of recombinant human adipocyte-derived leucine aminopeptidase expressed in Chinese hamster ovary cells. J Biochem (Tokyo) 2000;128:755-762.
12. Yamamoto N, Nakayama J, Yamakawa-Kobayashi K, Hamaguchi H, Miyazaki R, Arinami T: Identification of 33 polymorphisms in the adipocyte-derived leucine aminopeptidase (ALAP) gene and possible association with hypertension. Hum Mutat 2002;19:251-257.
13. Kaku T, Kamura T, Kinukawa N, Kobayashi H, Sakai K, Tsuruchi N, Saito T, Kawauchi S, Tsuneyoshi M, Nakano H: Angiogenesis in endometrial carcinoma. Cancer 1997;80:741-747.
14. Obermair A, Tempfer C, Wasicky R, Kaider A, Hefler L, Kainz C: Prognostic significance of tumor angiogenesis in endometrial cancer. Obstet Gynecol 1999;93:367-371.
15. Lee CN, Cheng WF, Chen CA, Chu JS, Hsieh CY, Hsieh FJ: Angiogenesis of endometrial carcinomas assessed by measurement of intra-tumoral blood flow, microvessel density, and vascular endothelial growth factor levels. Obstet Gynecol 2000;96:615-621.
16. Kandel J, Bossy-Wetzel E, Radvanyi F, Klagsbrun M, Folkman J, Hanahan D: Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma. Cell 1991;66:1095-1104.
17. Ferrara N, Henzel WJ: Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989;161:851-858.
18. Ko Y, Stiebler H, Nickenig G, Wieczorek AJ, Vetter H, Sachinidis A: Synergistic action of angiotensin II, insulin-like growth factor-I, and transforming growth factor-beta on platelet-derived growth factor-BB, basic fibroblastic growth factor, and epidermal growth factor-induced DNA synthesis in vascular smooth muscle cells. Am J Hypertens 1993;6:496-499.
19. Williams B, Baker AQ, Gallacher B, Lodwick D: Angiotensin II increases vascular permeability factor gene expression by human vascular smooth muscle cells. Hypertension 1995;25:913-917.
20. Otani A, Takagi H, Suzuma K, Honda Y: Angiotensin II potentiates vascular endothelial growth factor-induced angiogenic activity in retinal microcapillary endothelial cells. Circ Res 1998;82:619-628.
21. Nagasaka T, Nomura S, Okamura M, Tsujimoto M, Nakazato H, Oiso Y, Nakashima N, Mizutani S: Immunohistochemical localization of placental leucine aminopeptidase/oxytocinase in normal human placental, fetal and adult tissues. Reprod Fertil Dev 1997;9:747-953.
22. Wagatsuma S, Konno R, Sato S, Yajima A: Tumor angiogenesis, hepatocyte growth factor, and c-Met expression in endometrial carcinoma. Cancer 1998;82:520-530.
23. Yoshiji H, Kuriyama S, Kawata M, Yoshii J, Ikenaka Y, Noguchi R, Nakatani T, Tsujinoue H, Fukui H: The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: Possible role of the vascular endothelial growth factor. Clin Cancer Res 2001;7:1073-1078.
24. Miyajima A, Kosaka T, Asano T, Asano T, Seta K, Kawai T, Hayakawa M: Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis. Cancer Res 2002;62:4176-4179.
25. Mizutani S, Okano K, Hasegawa E, Sakura H, Yamada M: Aminopeptidase A in human placenta. Biochim Biophys Acta 1981;662:168-178.
26. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ: A human homolog of angiotensin-converting enzyme: Cloning and functional expression as a captopril-insensitive carboxypeptidase, J Biol Chem 2000;275:33238-33243.
27. Bhagwat SV, Lahdenranta J, Giordano R, Arap W, Pasqualini R, Shapiro LH: CD13/APN is activated by angiogenic signals and is essential for capillary tube formation. Blood 2001;97:652-659.
28. Yoshida T, Kaneko Y, Tsukamoto A, Han K, Ichinose M, Kimura S: Suppression of hepatoma growth and angiogenesis by a fumagillin derivative TNP470: Possible involvement of nitric oxide synthase. Cancer Res 1998;58:3751-3756.
29. Khin EE, Kikkawa F, Ino K, Kajiyama H, Suzuki T, Shibata K, Tamakoshi K, Nagasaka T, Mizutani S: Dipeptidyl peptidase IV expression in endometrial endometrioid adenocarcinoma and its inverse correlation with tumor grade. Am J Obstet Gynecol 2003;188:670-676.
30. Suzuki T, Kikkawa F, Ino K, Nagasaka T, Tamakoshi K, Mizutani S: Imbalance between neutral endopeptidase 24.11 and endothelin-1 expression in human endometrial carcinoma. Oncology 2001;60:258-267.
31. Miyashita H, Yamazaki T, Akada T, Niizeki O, Ogawa M, Nishikawa S, Sato Y: A mouse orthologue of puromycin-insensitive leucyl-specific aminopeptidase is expressed in endothelial cells and plays an important role in angiogenesis. Blood 2002;99:3241-3249.
32. Akada T, Yamazaki T, Miyashita H, Niizeki O, Abe M, Sato A, Satomi S, Sato Y: Puromycin insensitive leucyl-specific aminopeptidase (PILSAP) is involved in the activation of endothelial integrins. J Cell Physiol 2002;193:253-262.
33. Lessey BA, Albelda S, Buck CA, Castelbaum AJ, Yeh I, Kohler M, Berchuck A: Distribution of integrin cell adhesion molecules in endometrial cancer. Am J Pathol 1995;146:717-726.
34. Lin Q, Taniuchi I, Kitamura D, Wang J, Kearney JF, Watanabe T, Cooper MD: T and B cell development in BP-1/6C3/aminopeptidase A-deficient mice. J Immunol 1998;160:4681-4687.
35. Lo SS, Cheng DK, Ng TY, Wong LC, Ngan HY: Prognostic significance of tumour markers in endometrial cancer. Tumor Biol 1997;18:241-249.
36. Cherchi PL, Dessole S, Ruiu GA, Ambrosini G, Farina M, Capobianco G, Ambrosini A: The value of serum CA 125 and association CA 125/CA 19-9 in endometrial carcinoma. Eur J Gynaecol Oncol 1999;20:315-317.
37. Marth C, Fuith LC, Bock G, Daxenbichler G, Dapunt O: Modulation of ovarian carcinoma tumor marker CA-125 by gamma-interferon. Cancer Res 1989;49:6538-6542.
38. Hattori A, Matsumoto K, Mizutani S, Tsujimoto M: Genomic organization of the human adipocyte-derived leucine aminopeptidase gene and its relationship to the placental leucine aminopeptidase/oxytocinase gene. J Biochem (Tokyo) 2001;130:235-241.
39. Saric T, Chang SC, Hattori A, York, IA Markant S, Rock KL, Tsujimoto M, Goldberg AL: An IFN-gamma-induced aminopeptidase in the ER, ERAP1, trims precursors to MHC class I-presented peptides. Nat Immunol 2002;3:1169-1176.
40. Serwold T, Gonzalez F, Kim J, Jacob R, Shastri N: ERAAP customizes peptides for MHC class I molecules in the endoplasmic reticulum. Nature 2002;419:480-483.
41. York IA, Chang SC, Saric T, Keys JA, Favreau JM, Goldberg AL, Rock KL: The ER amino-peptidase ERAP1 enhances or limits antigen presentation by trimming epitopes to 8-9 residues. Nat Immunol 2002;3:1177-1184.